Monday, November 28, 2011 – After Market Close 

Green Baron 102^nd New “Stock Pick”

Amarantus BioSciences, Inc.

(OTCBB: AMBS – $.17 per share)

www.amarantus.com  

Common Shares Outstanding / 67.02M

Market Cap / $11.39M

52-Week High / $2.25

52-Week Low / $.06

Average Price/ .1487 (50-day) .2058 (200-day)

Average Volume / 20,499 (50-day) 55,029 (200-day)

Amarantus BioSciences Targets $3 Billion Global Market using its Patented and Proprietary MANF Platform to Treat Parkinson’s Disease

Pre-clinical Experiment Funded from the Michael J. Fox Foundation for Parkinson’s Research Confirms Potential for Benefits

Recent News: Amarantus BioSciences and Banyan Biomarkers announce Traumatic Brain Injury Research Collaboration

The Green Baron believes AMBS will be the next major winner from the biotech sector; This low priced stock could certainly trade in the dollars!

After last week’s announcement that Gilead Sciences (GILD) will acquire Pharmasset (VRUS) in an all cash $11 billion takeover, investors are searching for other biotech stocks that could be next.  Cash from the huge transaction is likely to find a home in a slew of up and coming biotech stocks.  "These deals tend to happen in waves," says Dan Veru, Palisade Capital Management's chief investment officer.

Although most of the money expected to chase biotech stocks in the coming weeks will go into more established names, The Green Baron Report believes it has identified the next major winner in the biotech sector among low-priced stocks, and we anticipate it will soon gain serious attention from investors:

The Green Baron Report officially selects Amarantus BioSciences, Inc. (OTCBB: AMBS) as our 102nd Green Baron “Stock Pick” since inception.  Results compiled from the most recent trade prior to dissemination of this report to the subsequent high will be closely monitored at www.thegreenbaron.com and through email updates to members.  We have very aggressive price projections for AMBS and believe the stock has huge upside potential based on several positive fundamental and technical factors.

TRADER’S NOTES:   AMBS is a fully reporting OTC Bulletin Board listed stock.  Active trading took place in AMBS shortly after it began to trade publicly in late July / early August at prices between .23 and .48 per share.  After hitting about .40 in mid-August, AMBS pulled back to trade in a range from mid-August through the end of October primarily between .10 and .20 per share.

The current shareholder base appears to be extremely supportive and a tightly held bunch.  AMBS has the ability to rally a huge amount on relatively low volume as evidenced on November 1 when The Green Baron Report issued a “Trading Alert” on AMBS.  That day, AMBS hit a high of .50 per share up as much as 163.15% from our profile price of .19 per share.  

We believe the pullback and consolidation over the past three weeks represents another fantastic opportunity to accumulate AMBS at low prices ahead of the next big move.  There appears to be solid support at .12 per share with little overhead resistance. 

Parkinson’s disease affects more than a million people in the United States alone and remains a disease with no cure.  Amarantus BioSciences has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson’s disease and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF").

Although Amarantus was founded in January 2008, it acquired the data and assets from its predecessor from Canada.  The previous Company successfully raised over $12 million, and although that Company took a wrong path, previous successes and errors provide extremely valuable information for AMBS going forward. 

The Green Baron Report has selected several primary reasons why our members and other investors should seriously consider accumulating AMBS common stock now: 

·         Proprietary and Patented Intellectual Property Covering Wide Array of Therapeutic Applications – Last month Amarantus received a Notice of Allowance from the United States Patent & Trademark Office ("USPTO"). The patent application claims include the discovery of mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF is a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of a range of apoptosis-related diseases including Parkinson's disease. This new patent complements Amarantus' existing collection of issued patents throughout Europe and pending patent applications worldwide on its proprietary MANF platform.

·         PhenoGuard Cell Lines – Amarantus will continue to file patents and build a strong intellectual property portfolio from their inventory of 88 cell lines referred to as “PhenoGuard Cell Lines”.  MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line, but the possibilities are limitless. These therapeutic proteins aim to address a host of major apoptosis-related diseases including Alzheimer’s disease, epilepsy, macular degeneration and traumatic brain injury.

·         Potential New Funding from The Michael J. Fox Foundation for Parkinson’s Research – Amarantus could make headlines should it continue to forge ahead with positive progress for a therapy or treatment for Parkinson’s disease.  Management maintains a positive relationship with the foundation, and a new funding arrangement would likely have very positive implications to the stock price of AMBS.

·         New Research Collaboration Announced Last Week – Amarantus and Banyan Biomarkers announced a collaboration agreement to evaluate MANF’s potential as a disease-modifying agent for the treatment of Traumatic Brain Injury, commonly known as concussions.  The goal is to pair the potential therapeutic treatments such as MANF alongside Banyan’s groundbreaking diagnostic test. 

·         Solid Leadership – The Management Team includes Chief Scientific Officer Dr. John Commissiong who discovered MANF in 2003.  The work pioneered by Dr. Commissiong has led to significant advancements in the field of astrocyte-neuron biology.  Dr. Commissiong believes that a fundamental understanding of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-related disorders.  President & CEO Gerald Commissiong is a Stanford graduate that went on to play professional football in Canada.  CFO Marc Faerber has over thirty years of experience and over nineteen of those in life sciences. His experience has spanned Fortune 500 companies to start-ups, and everything in between.

·         Dr. Owen Garrick Joins as Strategic Advisor – Clearly if you read more about Dr. Garrick you will understand his potential positive influence.  Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the President of the American Medical Association Foundation. Dr. Garrick previously held positions as Director of Corporate Strategy at McKesson Corporation, Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals and received his MD from Yale School of Medicine.

·         Valuation and Technicals – The market cap for AMBS is now less than $10 million, a mere speck of the potential value that the stock would command if progress continues to be positive.  At each milestone that is successfully met, AMBS would gain significant attention from other industry players.  AMBS stock is currently sitting on good technical support.

Green Baron Analysis:

Amarantus BioSciences is structured for success.  The Company has acquired and will build its intellectual property portfolio.  MANF represents a potential treatment for a range of diseases including Parkinson’s, and the Company last month received its Notice of Allowance from the United States Patent & Trademark Office.  This was a significant development that alone could be worth far more than today’s trading value in the stock.

The management team, the advisory team and its strategic advisors are as experienced as any small biotech company we have seen.  The involvement of several members is a strong testament to this Company without even looking further.  We urge members and investors to visit the Company’s website or read the end of this report to view the resumes and background of this veteran team.

Biotechnology stocks can be challenging to value because it takes so long be granted FDA approval and begin to produce revenue.  The valuation comes from positive milestones that are successfully met, and the potential markets for the treatments that are being developed.  The Company already has years of data and development of MANF under its belt, and its Chief Science Officer and Founder Dr. John Commissiong is clear on where to take this next. 

The Green Baron Report is confident that Amarantus is gaining respect in the biotech community.  We view the stock as a bargain at its current valuation, and we believe AMBS should command a $50 to $100 million valuation when granted approval to begin human clinical trials.  Due to the fact that there is currently no cure for Parkinson’s, any treatment demonstrating efficacy and safety could get fast tracked through the FDA testing and clearance process. 

The sky is the limit for AMBS, but a $50 to $100 million valuation would put AMBS at a price of .74 to $1.49 per share at the current share count.  Therefore, we believe our members would be wise to accumulate at or near our current profile price. 

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. (“Amarantus”) is focused on the discovery and development of therapeutic proteins with the potential to address critically important biological pathways involved in the treatment human diseases.

The Company’s lead program MANF is aimed at developing products to address the underlying Programmed Cell Death (Apoptosis) associated a wide range of devastating human disorders. With a global trend towards a prolonged life expectancy due to novel therapies and emerging countries gaining access to critical medical care, the development of Apoptosis-related treatments represents a significant market opportunity that addresses a critical unmet medical need: safely and effectively improving currently-approved patients’ treatments.

Amarantus’ business strategy, utilizing Amarantus’ seasoned Management Team, world-class Scientific Advisory Board and Board of Directors, is to employ our PhenoGuard Drug Discovery Engine to discover medically-relevant secreted human proteins, scientifically establish their therapeutic potential, develop pre-clinical and clinical programs to further their development, and advance them through successive de-risking milestones to maximize their commercial potential while making them attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies.

About MANF

MANF is a protein that corrects protein misfolding. Protein misfolding is one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson's Research. The Company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines." MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company's inventory of PhenoGuard Cell Lines.

Science and Biology

Apoptosis

Apoptosis is the term used to describe Programmed Cell Death (PCD) in multicellular organisms. Apoptosis is one of the main types of PCD which involves a cascade of biochemical events leading to specific changes in the cell at the level of the nucleus, cytoplasm and plasma membrane, ultimately to cell death.

Apoptosis differs from necrosis, the other major type of cell death, in that the processes associated with apoptosis in disposal of cellular debris tend not to induce inflammation and further damage to the organism as a whole. Necrosis is a form of traumatic cell death that results from acute cellular injury. Apoptosis in contrast to necrosis, confers advantages during an organism’s life cycle. Since the 1990′s research has increased substantially in the field of apoptosis. It has been shown that defective apoptotic processes in humans and animals are related to a variety of diseases. Excessive apoptosis has been implicated in neurodegenerative diseases like Parkinson’s and Alzheimer’s diseases, and diseases resulting from ischemic damage. Deficient apoptosis on the other hand can lead to uncontrolled cell proliferation, as occurs in cancer.

The development and careful application of therapies that mediate this biological pathway may lead to significantly improved patient outcomes in a verity of severe disorders

Astrocytes

Proliferation of DA Neuron by of two PhenoGuard

Astrocytes are brain cells that make up a large portion of the cells in the Central Nervous System. Generally speaking, the function of astrocytes is support neurons throughout their development. The support they provide is localized, which means that astrocytes from a specific brain region act more powerfully on neurons from that particular brain region than from any other. Astrocytes mediate three critical brain functions:

1.    Neuroprotection: Helping to protect neurons from death

2.    Neurogenesis: Helping to generate new neurons from stem cells

3.    Synaptogenesis: Helping to establish connections between neurons

Astrocytes perform these tasks by producing and secreting molecules that affect neurons. Using our proprietary method, we are able to identify these highly relevant proteins with biological activity for the protection of neurons and other cells associated with the treatment of devastating human disorders. The first drug candidate identified from this platform is MANF.

Discovery

PhenoGuard Cell Line Library

Amarantus Therapeutics has pioneered the development of immortalized mammalian cells that retain the phenotype of their parent cell. Our proprietary PhenoGuard immortalization process, which does not utilize Genetic Engineering techniques to insert foreign DNA into the genome, allows for the development of cell lines from both dividing and non-dividing cell that express the same genes as their Parent cells.

To date, Amarantus has developed a library of 80 cell lines engineering from Astrocytes and Neurons from various regions of the Central Nervous System. Our lead candidate AMRS001 was derived from the very PhenoGuard Cell Line ever developed. Amarantus intends to use this resource to advance Therapeutic Discovery and Target Validation.

PhenoGuard Protein Discovery Engine

Amarantus Therapeutics has developed a robust discovery platform PhenoGuard Protein Discovery Engine that allows Amarantus scientists to rapidly discover novel secreted human proteins with biological activity for specific indications. Our Platform consists of our PhenoGuard Cell Line Library and highly sensitive Target Validation cell culture systems that provide accurate results and allow our scientists to make better go/no-go decisions. The first application of our Protein Discovery Engine was in the discovery of MANF from astrocytes.

Therapeutic Development

Parkinson’s Disease

Parkinson’s disease (PD) is a neurodegenerative disorder and belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells. The four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination. As these symptoms become more pronounced, patients may have difficulty walking, talking, or completing other simple tasks. PD usually affects people over the age of 50. Early symptoms of PD are subtle and occur gradually.

In some people the disease progresses more quickly than in others. As the disease progresses, the shaking, or tremor, which affects the majority of PD patients may begin to interfere with daily activities. Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions. There are currently no blood or laboratory tests that have been proven to help in diagnosing sporadic PD. Therefore the diagnosis is based on medical history and a neurological examination. The disease can be difficult to diagnose accurately. Doctors may sometimes request brain scans or laboratory tests in order to rule out other diseases.

Current approved therapies treat only the symptoms of Parkinson’s disease. There is an urgent medical need for curative treatments for Parkinson’s disease that fills the fundamental gap in treatment: arresting disease progression. MANF, a neurotrophic factor indicated for the treatment of Parkinson’s disease, offers the promise of safely and effectively protecting dopamine producing neurons from death and rejuvenating dying cells to ultimately stop the progress of Parkinson’s disease and restore normal function to patients.

Ischemic Heart Disease

Ischemic Heart Disease (IHD) is a disease characterized by reduced blood supply to the heart muscle, usually due to atherosclerosis of the coronary arteries. Its risk increases with age, smoking, high cholesterol levels, diabetes and hypertension. It is more common in men and those who have a family history of IHD.

Symptoms of stable IHD include angina and decreased exercise tolerance. Unstable IHD presents itself as chest pain or other symptoms at rest, or rapidly worsening angina. Diagnosis of IHD is with an electrocardiogram, blood tests (cardiac markers), cardiac stress testing or a coronary angiogram. Depending on the symptoms and risk, treatment may be with medication, percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack is caused by interruption of blood supply to parts of the heart, causing some heart cells to die. This is most commonly due to blockage of a coronary artery associated with an atherosclerotic plaque, which is an unstable collection of lipids and white blood cells in the wall of an artery. The resulting ischemia and associated oxygen shortage, if left untreated for a sufficient period of time, can cause necrosis followed by apoptosis or Programmed Cell Death in the affected parts of the myocardium. Classical symptoms of acute myocardial infarction include sudden chest pain, shortness of breath, nausea, vomiting, palpitations and sweating. Approximately 25% of all myocardial infarctions are silent, without chest pain or other symptoms.

Ischemic Heart Disease is the most common cause of death in most Western countries, and a major cause of hospital admissions. There is limited evidence for population screening, but prevention is used both to prevent IHD and to decrease the risk of complications. Myocardial Infarctions are one of the leading causes of death for both men and women all over the world. Important risk factors are previous cardiovascular disease, older age, tobacco smoking, high blood levels of certain lipids and low levels of high density lipoprotein, diabetes, high blood pressure, obesity, chronic kidney disease, excessive alcohol consumption, and chronic high stress levels.

The common theme of the many forms of IHD, including myocardial infarction, that have been characterized is the pathway of apoptosis-related cell death associated with reperfusion related injuries. MANF has been shown to be robustly upregulated, and to protect heart muscle in reperfusion models of cardiac ischemia.

Recent Key Announcements

Tuesday, November 22, 2011 – Amarantus BioSciences and Banyan Biomarkers announce Traumatic Brain Injury Research Collaboration - SUNNYVALE, CA – November 15, 2011 – Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), today announced a collaboration agreement to evaluate MANF’s potential as a disease-modifying agent for the treatment of Traumatic Brain Injury.

“Traumatic Brain Injuries, commonly known as concussions, are the result of devastating acute blows to the head as are typically seen in recreational sports such as football,” said Gerald Commissiong, Chief Scientific President & CEO of Amarantus. “Given my football background, I am hopeful that MANF will prove effective in treating these injuries and believe that this area of research could become an important part of Amarantus’ overall strategy going.”

“MANF appears to have a profile of activity in cerebral ischemia that is consistent with a potential therapeutic benefit in Traumatic Brain Injury,” said Dr. Andreas Jeromin, PhD, Director of Business Development and Assay Core Services at Banyan, “We are hopeful to be able to pair potential therapeutic treatments such as MANF alongside our groundbreaking diagnostic test going forward. This study will also utilize novel biomarkers of neurotoxicity developed by Banyan to assess drug safety.”

Tuesday, November 15, 2011 - Amarantus BioSciences’ Gerald and Dr. John Commissiong Selected as Black Money’s “50 Most Important African-Americans in Technology - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein, today announced that both Gerald and Dr. John Commissiong are among the Bay Area selectees for the 12^th Annual 50 Most Important African-Americans in Technology. The selectees will gather in Washington, D.C. January 14-15, 2012 for the 12^th Annual Innovation and Equity Symposium themed: "Capitalizing Creativity: Innovation and Job Creation." At the Innovation and Equity Symposium, participants will discuss a variety of relevant topics relating to African-Americans including the new America Invents Act and the low participation of African-American students in math and science courses.

“We have worked tremendously hard over the past several years to discover, patent and develop molecules to treat patients suffering from Parkinson’s and other CNS diseases,” said John Commissiong, Chief Scientific Officer of Amarantus. “We are honored to be recognized for our efforts as part of this prestigious group.”

Amarantus was also among the companies participating in the Catapult Innovation Showcase, an effort to identify the most promising high growth, job creating companies among the 1,000 patents gained each year by African-Americans. Amarantus recently received a Notice of Allowance from the U.S. Patent & Trademark Office covering MANF’s discovery and therapeutic applications, which complements the Company’s existing patent portfolio in Europe and global patent-pending portfolio. Amarantus’ most advanced program is focused on developing MANF as a disease-modifying therapy for Parkinson's disease.  

Monday, November 14, 2011 - Amarantus Biosciences, a Promising Biotech Company in Development - MIAMI, Nov. 14, 2011 (GLOBE NEWSWIRE) Founded in California in 2008, Amarantus Biosciences, Inc. (OTCBB:AMBS) is now poised to take the biotech world by storm with their proprietary new technology. It's called Mesencephalic-Astrocyte-derived Neurotrophic Factor, or MANF, for short. Discovered by combining research conducted at the National Institutes of Health throughout the 1990s, this highly potent protein treatment for diseases caused by cell death (apoptosis) is currently in pre-clinical development. Their first target is Parkinson's disease.

October was a breakthrough month for Amarantus Biosciences as it announced the Notice of Allowance from the United States Patent & Trademark Office (USPTO). This new patent complements Amarantus' existing collection of issued patents throughout Europe and pending patent applications worldwide. The company also completed a closed a $10M Equity Funding Facility with Centurion Private Equity, LLC.

In striving to put together a highly qualified advisory board, Amarantus recently appointed the President of American Medical Association Foundation Dr. Owen Garrick as Strategic Advisor. Dr. Garrick previously held positions as Director of Corporate Strategy at McKesson Corporation, Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals and received his MD from Yale School of Medicine. The prestigious team continues to grow, and the list reads like a who's who of biotech companies.

Why all the support? It could be because Parkinson's disease represents a $3 billion global market and affects more than a million people in the U.S. alone. The buzz on Wall Street surrounding Amarantus is the grant from the Michael J. Fox Foundation for Parkinson's Research. This money funded a pre-clinical experiment that confirmed what was previously reported in the Journal of Neuroscience in 2009 - that MANF significantly reduces the behavioral deficits caused by the neurotoxin 6-OHDA in a standard animal model of Parkinson's disease.

"Since 2003, 14 papers have been published in highly-respected peer-reviewed journals describing MANF's ability to rescue neurons from death in a variety of cellular and animal models of CNS disease," said John Commissiong PhD, the Chief Scientific Officer of Amarantus who discovered MANF.

By 2032, the incidence of Parkinson's disease is expected to double, and as of yet, there is no effective treatment. Amarantus is dedicated to changing that.

What's next after that? CEO Gerald Commissiong guarantees that Amarantus will continue to file patents and build a strong intellectual property portfolio from their inventory of 88 cell lines referred to as "PhenoGuard Cell Lines". MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line, but the possibilities are limitless. These therapeutic proteins aim to address a host of major apoptosis-related diseases including Alzheimer's disease, epilepsy, macular degeneration and traumatic brain injury. In layman's terms, this is one to watch.

Tuesday, November 1, 2011 - Amarantus BioSciences Expands Corporate Strategy - Amarantus BioSciences, Inc. today provided shareholders with an update on its corporate strategy. Amarantus will utilize its core scientific understanding of Parkinson’s disease and related areas of neuroscience to identify and advance product development opportunities that fill gaps of significant unmet medical need. The Company has initiated a corporate mandate to identify complementary assets to diversify and strengthen its pipeline and will work with its current stakeholders as well as experts in the field to execute upon this strategy.

“Amarantus intends to seize upon the opportunities created by inefficiencies in the marketplace for Parkinson’s disease and Central Nervous System disorder-related product development programs to dramatically alter the paradigm for patients suffering from these terrible diseases,” said Gerald Commissiong, Amarantus’ newly appointed President and CEO. “By adjusting our corporate strategy to potentially bolster our pipeline, we hope to reduce our overall enterprise risk and shorten the time horizon of return on investment for shareholders.”

Amarantus’ most advanced program is focused on developing MANF as a disease-modifying therapy for Parkinson's disease. Amarantus is currently developing its strategic plan for MANF’s translational development in Parkinson’s disease and expects to update the marketplace with projected milestones and timelines in early 2012. The Company recently received a Notice of Allowance from the U.S. Patent & Trademark Office covering MANF’s discovery and therapeutic applications, which complements the Company’s existing patent portfolio in Europe and global patent-pending portfolio.

Tuesday, October 25, 2011 - Amarantus BioSciences Appoints Dr. Owen Garrick as Strategic Advisor - Amarantus BioSciences, Inc. today announced that Dr. Owen Garrick, MD, MBA has joined the Company as Strategic Advisor to the Company's Board of Directors. In this advisory role, Dr. Garrick will provide insight on fund raising, clinical development preparation and strategic transactions.

"I am pleased to join Amarantus at this exciting time in the Company's development cycle," said Dr. Garrick. "The MANF platform represents an attractive technology with the potential to treat a number of apoptosis-related disorders, beginning with Parkinson's disease. I will be working closely with the team to fully develop the infrastructure to successfully move the MANF programs into clinical development."

Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.

"We are pleased to welcome Owen to Amarantus as we center our corporate strategy on developing our MANF Parkinson's disease program towards the clinic," said Martin D. Cleary, Chairman & CEO of Amarantus. "Dr. Garrick's experience in fund raising and innovative corporate transactions will greatly assist Amarantus in evaluating synergistic strategies to advance Amarantus' mission of getting sorely needed therapies to patients with Parkinson's disease."

Thursday, October 20, 2011 - Amarantus BioSciences Receives Notice of Allowance for U.S. Patent Covering MANF Discovery - Amarantus BioSciences, Inc. (OTC.BB: AMBS), a biotechnology company developing a first-in-class disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis, announced today that it has received a Notice of Allowance from the United States Patent & Trademark Office ("USPTO"). The patent application claims include the discovery of mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF is a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of a range of diseases apoptosis-related including Parkinson's disease. The patent will broaden overall protection for the Company's therapeutic development of MANF. The patent claims include compositions of matter and methods of use for MANF, and other related compounds. This new patent complements Amarantus' existing collection of issued patents throughout Europe and pending patent applications worldwide on its proprietary MANF platform.

"This patent allowance notice from the USPTO is a major milestone for the Company's intellectual property pursuits and significantly strengthens our proprietary position in the field. Moreover, this latest patent will further protect Amarantus' intellectual property as the Company expands its pipeline of first-in-class therapeutics to address a number of indications," said Martin D. Cleary, Chief Executive Officer. "We will continue to broadly file and prosecute patent applications to build a strong intellectual property portfolio around our proprietary technology and to further strengthen our leadership position in the emerging field of novel MANF-based therapeutics."

Tuesday, August 2, 2011 - Amarantus BioSciences Presents Summary of Peer-Reviewed Data for Parkinson's Program - Scientific Literature Provides Compelling Rationale for Further Development - Amarantus BioSciences, Inc. (OTC.BB: AMBS), a biotechnology company developing MANF, a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis, today presented a summary of the peer-reviewed findings reported to date in prominent scientific journals that provide a compelling scientific rationale for the further development of the Company's Parkinson's program. The publications, appearing in seven different scientific journals, indicate that MANF's molecular properties make it an attractive development candidate for the treatment of Parkinson's disease. This announcement follows data reported last week, in which Amarantus reproduced key pre-clinical data that provides a sound scientific rationale to focus the MANF Parkinson's development program on the protocols required to gain regulatory approval to initiate human clinical studies.

"The scientific community is generally quite conservative when it comes to the evaluation of new drug candidates for the treatment of poorly-served conditions such as Parkinson's disease," said Martin D. Cleary, Chief Executive Officer of Amarantus. "The breadth of data published over the last 8 years in these leading scientific journals represents significant external scientific validation of MANF's potential and gives the Company a solid foundation to further invest in its Parkinson's program to confirm MANF's ability to slow or reverse the progression of this devastating disease."

MANF is a novel protein that was discovered from Amarantus' PhenoGuard Protein Discovery Engine, which uses the Company's proprietary cell lines to discover neurotrophic factors with activity against specific neurodegenerative diseases. Neurotrophic factors are proteins that protect neurons from various insults and are promising drug candidates for Parkinson's and other neurodegenerative diseases. The data reported below identifies a unique mechanism of action for MANF among neurotrophic factors:

·         In research reported in 2010 in The Journal of Biological Chemistry [286:2675-2680] researchers concluded that MANF has a unique mechanism to rescue neurons dying by apoptosis;

·         In a review published in 2010 in Developmental Neurobiology, [70:360-371], researchers reviewed the breadth of published data and concluded that MANF is a potential therapeutic protein for the treatment of Parkinson's disease;

·         In research reported in 2009 The Journal of Neuroscience, [29(30):9651-9659], MANF demonstrated neurorestorative properties in a rodent model of Parkinson's, MANF was also readily distributed throughout the striatum and demonstrated significant therapeutic potential for the treatment of Parkinson's disease;

·         In research reported in 2009 in Proceedings of the National Academy of Sciences, [106:2429-2434], researchers concluded that MANF is essential for the maintenance of dopamine positive neurites and dopamine levels in Drosophila. Further, the knockout of MANF in Drosophila leads to degeneration of axonal bundles in the nervous system;

·         In a review published in 2007 in Science, [411:pe60], researchers reported that MANF was part of a new class of neurotrophic factors that may present advantages versus previously studied neurotrophic factors for Parkinson's disease;

·         In research reported in 2006 in NeuroReport, [17:293-297], researchers concluded that MANF increases the release of the neurotransmitter GABA from pre-synaptic nerve terminals in the substantia nigra, which in turn may dampen the excitotoxic action of excessive glutamate that has been associated with dopaminergic cell death;

·         In research reported in 2003 in Journal of Molecular Neuroscience [20: 173-188], researchers announced the discovery of MANF and reported that MANF protects the dopaminergic neurons that degenerate in Parkinson's disease in vitro.

"Combined with the results reported last week, these scientific publications provide significant independent validation for Amarantus' lead candidate MANF's potential to address the apoptotic neuronal death associated with Parkinson's disease," said John W. Commissiong, Chief Scientific Officer of Amarantus and discover of MANF. "The results published to date indicate that there are potentially several other CNS-related medical conditions where MANF could play a vital role due to its novel mechanism of action for rescuing apoptotic neurons. We fully intend to develop additional strategies to maximize the value of the extensive intellectual property portfolio the Company owns covering MANF to treat nervous system disorders."

Management

Gerald E. Commissiong – President & CEO

Mr. Commissiong was appointed President & CEO of Amarantus BioSciences in October 2011. In March 2011, Mr. Commissiong was promoted to Chief Operating Officer of Amarantus, where his duties included strategic transactions, licensing, research collaborations, mergers & acquisitions, fund raising and investor relations. From August 2009 until March 2011, he served as Chief Business Officer where he was responsible for business development and corporate development. In 2008, Mr. Commissiong co-founded Amarantus with Dr. John Commissiong PhD and served as its President & CEO until August 2009. In that timeframe, Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and executive talent to Amarantus to allow for the further development of the technologies. Mr. Commissiong has served as a Director of Amarantus since 2008. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus Financial Decisions from Stanford University.

John W. Commissiong, PhD – Chief Scientific Officer

Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the company in 2009. From 2000 through 2008 Dr. Commissiong served as the CSO of Neurotrophics Inc & Prescient Neuropharma Inc. Dr. Commissiong has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as understanding the fundamental underlying biology of protoplasmic type-1 astrocytes that secrete neurotrophic factors. He was Chief of the Neural Transplantation Unit, NINDS-NIH, from 1989-94 where his research focused on identifying therapeutic approaches to spinal cord injury. Dr. Commissiong was Head of the Neurotrophic Factors Group, NINDS-NIH, from 1994-97 where he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific Central Nervous System disorders. He co-founded Prescient Neuropharma in 1999, and discovered MANF in 2003. MANF is currently in preclinical development for the treatment of Parkinson’s disease. The work pioneered by Dr. Commissiong has led to significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes that a fundamental understanding of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-related disorders.

Dr. Commissiong did his Postdoctoral work in the Lab Preclin Pharmac, NIMH-NIH, concentrating on the application of quadrupole mass spectrometry in the analysis of neurotransmitters. He holds a Ph.D. in Neurophysiology from the University of Southampton, an M.Sc. in Biochemical Pharmacology from the University of Southampton, and a B.S. in Biology and Chemistry from the University of the West Indies.

Marc E. Faerber – Controller / CFO

Mr. Faerber has over thirty years of experience and over nineteen of those in life sciences. His experience has spanned Fortune 500 companies to start-ups, and everything in between. During the past ten years Mr. Faerber has been providing financial, business and advisory services to a broad base of start-up companies primarily in the fields of cardiology, gastroenterology, orthopedics, diagnostics and biotechnology.

Mr. Faerber has extensive transactional experience, including considerable experience in establishing international organizations throughout Europe and parts of Asia, international technology licensing and distribution transactions, mergers and acquisitions, and numerous funding transactions, including an initial public offering as well as other international business structural issues. During Mr. Faerber’s career he has held various positions in finance and corporate management including CFO, CEO and Director. Mr. Faerber started his career working for KPMG, is a certified public accountant, and has a Bachelor of Sciences in Business Administration from Providence College.

Scientific Advisory Board

Lawrence M. Schwartz, PhD

Dr. Lawrence M. Schwartz was appointed in 2010 as the first Isenberg Professor of Integrative Science at the University of Massachusetts. Dr. Schwartz is a Professor in the Biology Department at the University of Massachusetts, as well as the Founding Director of the Pioneer Valley Life Sciences Institute in Springfield MA where he served as Scientific Director from 2004 until 2010. He also served as the Director of the Center of Excellence in Apoptosis. His laboratory examines the molecular mechanisms that mediate cell death during normal development and in pathology. One avenue of research focuses in Acheron, a novel gene cloned in the Schwartz laboratory that regulates the differentiation and death of skeletal muscle, and may play a role in the metastatic behaviors of some soft tissue tumors. A second line of investigation examines the role of ubiquiton E3 ligases Parkin and Human Homolog of Ariadne-1 in dopaminergic neuron survival.

Greg Gerhardt, PhD

Dr. Gerhardt’s laboratory focuses on studies of the dopamine and glutamate neurotransmitter systems in animal models of Parkinson’s disease. For these studies, his lab uses both the 6-hydroxydopamine-treated rat model and the MPTP-treated primate model of Parkinson’s disease. Using his microsensor techniques, Dr. Gerhardt’s lab has investigated the release and uptake of dopamine in the striatum and substantia nigra of the normal and Parkinsonian brain. A major finding from these studies is that there is a severe disruption of dopamine regulation in the Parkinsonian brain. This disruption of the control of dopamine may relate to some of the movement problems seen in this CNS disease. His laboratory is currently investigating the use of growth factors, such as GDNF, to restore function to damaged dopamine neurons. His laboratory has recently shown that GDNF can restore function to damaged dopamine neurons in rats and monkeys. This forms the basis for the Morris K. Udall Parkinson’s Disease Center of Excellence.

William Marks, MD

Dr. William Marks, a specialist in epilepsy and movement disorders, has extensive experience in treating Parkinson’s disease and other movement disorders with brain stimulators. He earned a medical degree at Johns Hopkins University and completed a residency and a fellowship in neurology at UCSF Medical Center. He currently is medical director of the UCSF Center for the Surgical Treatment of Movement Disorders. At the Veterans Affairs Medical Center in San Francisco, he is director of the Parkinson’s Disease Research, Education and Clinical Center and the Comprehensive Epilepsy Center.

Contact:

Amarantus BioSciences, Inc.
Gerald E. Commissiong
(408) 737-2734 ext.102
pr@amarantus.com
www.amarantus.com

NOTE: To receive future updates delivered to your email regarding Amarantus BioSciences, Inc. (OTCBB: AMBS) and other companies covered by The Green Baron Report, please visit www.TheGreenBaron.com and click any “Join Now” icon.